Advances in non-operative treatment of advanced hypopharyngeal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20210520-00042

Abstract

Abstract:

Hypopharyngeal squamous cell carcinoma has a high degree of malignancy, hidden location, atypical early symptoms, most patients have reached advanced stage at the time of treatment. Surgical treatment will cause patients to lose laryngeal function and poor postoperative quality of life. The combined application of non-operative therapies such as radiotherapy and chemotherapy can improve the larynx preservation rate of patients and obtain a survival rate similar to that of surgical treatment. Targeted therapy has achieved better results in the treatment of hypopharyngeal squamous cell carcinoma, and immunotherapy has also made great progress in the treatment of head and neck squamous cell carcinoma, which brings new hope for patients with hypopharyngeal squamous cell carcinoma.

Key words: Hypopharyngeal neoplasms, Molecular targeted therapy, Immunotherapy, Combined modality therapy, Non-operative treatment

Zhang Rui, Feng Enzi, Ren Yanxin, Li Xiaojiang. Advances in non-operative treatment of advanced hypopharyngeal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(4): 233-236.

References 33

[1]	Chen X, Li C, Chen W, et al. Metformin inhibits the development of hypopharyngeal squamous cell carcinoma through circ_0003214-mediated miR-489-3p-ADAM10 pathway[J]. J Oncol, 2021, 2021: 2265475. DOI: 10.1155/2021/2265475. doi: 10.1155/2021/2265475
[2]	Kim JW, Kim MS, Kim SH, et al. Definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy in resectable stage Ⅲ/Ⅳ hypopharyngeal cancer[J]. Cancer Res Treat, 2016, 48(1): 45-53. DOI: 10.4143/crt.2014.340. doi: 10.4143/crt.2014.340
[3]	Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments[J]. J Laryngol Otol, 2018, 132(5): 385-400. DOI: 10.1017/S0022215118000555. doi: 10.1017/S0022215118000555 pmid: 29891019
[4]	Iwae S, Fujii M, Hayashi R, et al. Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy[J]. Int J Clin Oncol, 2017, 22(6): 1001-1008. DOI: 10.1007/s10147-017-1151-9. doi: 10.1007/s10147-017-1151-9
[5]	Kim YJ, Lee R. Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: a population-based study[J]. Cancer Med, 2018, 7(12): 5889-5900. DOI: 10.1002/cam4.1811. doi: 10.1002/cam4.1811
[6]	Gupta T, Sinha S, Ghosh-Laskar S, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial[J]. Radiat Oncol, 2020, 15(1): 218. DOI: 10.1186/s13014-020-01666-5. doi: 10.1186/s13014-020-01666-5
[7]	Susko MS, Lazar AA, Dhar S, et al. Improved tumor control related to radiotherapy technological development for hypopharyngeal cancer[J]. Laryngoscope, 2021, 131(2): E452-E458. DOI: 10.1002/lary.28726. doi: 10.1002/lary.28726
[8]	Beddok A, Vela A, Calugaru V, et al. Proton therapy for head and neck squamous cell carcinomas: from physics to clinic[J]. Cancer Radiother, 2019, 23(5): 439-448. DOI: 10.1016/j.canrad.2019.05.015. doi: S1278-3218(19)30150-7 pmid: 31358445
[9]	Beddok A, Feuvret L, Noël G, et al. Boost in proton for locally advanced nasopharyngeal carcinoma: a curie institute experience[J]. Cancer Radiother, 2019, 23(4): 304-311. DOI: 10.1016/j.canrad.2019.01.003. doi: S1278-3218(19)30089-7 pmid: 31138519
[10]	Santa Cruz O, Tsoutsou P, Castella C, et al. Locoregional control and toxicity in head and neck carcinoma patients following helical tomotherapy-delivered intensity-modulated radiation therapy compared with 3D-CRT data[J]. Oncology, 2018, 95(2): 61-68. DOI: 10.1159/000489217. doi: 10.1159/000489217
[11]	Moreno AC, Frank SJ, Garden AS, et al. Intensity modulated proton therapy (IMPT)-The future of IMRT for head and neck cancer[J]. Oral Oncol, 2019, 88: 66-74. DOI: 10.1016/j.oraloncology.2018.11.015. doi: S1368-8375(18)30424-X pmid: 30616799
[12]	肖月, 邱英鹏, 史黎炜, 等. 螺旋断层放射治疗系统在我国公立医院应用现状分析[J]. 中国医学装备, 2020, 17(12): 8-12. DOI: 10.3969/J.ISSN.1672-8270.2020.12.003. doi: 10.3969/J.ISSN.1672-8270.2020.12.003
[13]	Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial[J]. Ann Oncol, 2017, 28(9): 2206-2212. DOI: 10.1093/annonc/mdx299. doi: 10.1093/annonc/mdx299 pmid: 28911070
[14]	Haddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions[J]. Ann Oncol, 2018, 29(5): 1130-1140. DOI: 10.1093/annonc/mdy102. doi: S0923-7534(19)34558-2 pmid: 29635316
[15]	Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase Ⅲ trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation[J]. J Natl Cancer Inst, 2015, 108(4): djv368. DOI: 10.1093/jnci/djv368. doi: 10.1093/jnci/djv368
[16]	Enokida T, Ogawa T, Homma A, et al. A multicenter phase Ⅱ trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck[J]. Cancer Med, 2020, 9(5): 1671-1682. DOI: 10.1002/cam4.2852. doi: 10.1002/cam4.2852
[17]	Zumsteg ZS, Kim S, David JM, et al. Impact of concomitant chemoradiation on survival for patients with T_1-2N₁ head and neck cancer[J]. Cancer, 2017, 123(9): 1555-1565. DOI: 10.1002/cncr.30508. doi: 10.1002/cncr.30508
[18]	Colevas AD, Yom SS, Pfister DG, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018[J]. J Natl Compr Canc Netw, 2018, 16(5): 479-490. DOI: 10.6004/jnccn.2018.0026. doi: 10.6004/jnccn.2018.0026
[19]	Hamauchi S, Yokota T, Mizumachi T, et al. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin[J]. Int J Clin Oncol, 2019, 24(5): 468-475. DOI: 10.1007/s10147-018-01392-9. doi: 10.1007/s10147-018-01392-9 pmid: 30656463
[20]	Iberri DJ, Colevas AD. Balancing safety and efficacy of epidermal growth factor receptor inhibitors in patients with squamous cell carcinoma of the head and neck[J]. Oncologist, 2015, 20(12): 1393-1403. DOI: 10.1634/theoncologist.2015-0177. doi: 10.1634/theoncologist.2015-0177 pmid: 26446236
[21]	Taberna M, Oliva M, Mesía R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma[J]. Front Oncol, 2019, 9: 383. DOI: 10.3389/fonc.2019.00383. doi: 10.3389/fonc.2019.00383 pmid: 31165040
[22]	王孝深, 胡超苏. 抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用[J]. 中国癌症杂志, 2018, 28(12): 881-887. DOI: 10.19401/j.cnki.1007-3639.2018.12.001. doi: 10.19401/j.cnki.1007-3639.2018.12.001
[23]	Janoray G, Pointreau Y, Alfonsi M, et al. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial[J]. Eur J Cancer, 2020, 133: 86-93. DOI: 10.1016/j.ejca.2020.04.009. doi: 10.1016/j.ejca.2020.04.009
[24]	Tian X, Xuan Y, Wu R, et al. Nimotuzumab combined with induction chemotherapy and concurrent chemoradiotherapy in unresec-table locally advanced hypopharyngeal carcinoma: a single institution experience in China[J]. Cancer Manag Res, 2020, 12: 3323-3329. DOI: 10.2147/CMAR.S248392. doi: 10.2147/CMAR.S248392 pmid: 32494195
[25]	Ferris RL, Geiger JL, Trivedi S, et al. Phase Ⅱ trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer[J]. Ann Oncol, 2016, 27(12): 2257-2262. DOI: 10.1093/annonc/mdw428. doi: 10.1093/annonc/mdw428 pmid: 27733374
[26]	Guo Y, Ahn MJ, Chan A, et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase Ⅲ trial[J]. Ann Oncol, 2019, 30(11): 1831-1839. DOI: 10.1093/annonc/mdz388. doi: S0923-7534(20)32596-5 pmid: 31987090
[27]	Chaib I, Cai X, Llige D, et al. Osimertinib and dihydroartemi-sinin: a novel drug combination targeting head and neck squamous cell carcinoma[J]. Ann Transl Med, 2019, 7(22): 651. DOI: 10.21037/atm.2019.10.80. doi: 10.21037/atm.2019.10.80
[28]	Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer[J]. Cancer Treat Rev, 2020, 84: 101977. DOI: 10.1016/j.ctrv.2020.101977. doi: 10.1016/j.ctrv.2020.101977
[29]	Zhou K, Li Y, Liao W, et al. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: a cost-effectiveness analysis from Chinese perspective[J]. Oral Oncol, 2020, 107: 104754. DOI: 10.1016/j.oraloncology.2020.104754. doi: 10.1016/j.oraloncology.2020.104754
[30]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018, 81: 45-51. DOI: 10.1016/j.oraloncology.2018.04.008. doi: 10.1016/j.oraloncology.2018.04.008
[31]	Yen CJ, Kiyota N, Hanai N, et al. Two-year follow-up of a randomized phase Ⅲ clinical trial of nivolumab vs. the investigator’s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)[J]. Head Neck, 2020, 42(10): 2852-2862. DOI: 10.1002/hed.26331. doi: 10.1002/hed.26331
[32]	Galvis MM, Borges GA, Oliveira TB, et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2020, 150: 102966. DOI: 10.1016/j.critrevonc.2020.102966. doi: 10.1016/j.critrevonc.2020.102966
[33]	Kareemaghay S, Tavassoli M. Clinical immunotherapeutic approaches for the treatment of head and neck cancer[J]. Int J Oral Maxillofac Surg, 2019, 48(4): 419-436. DOI: 10.1016/j.ijom.2018.10.012. doi: 10.1016/j.ijom.2018.10.012